BioPubI zoomed in and felt very happy at the end of webcast that I had shares. They did explain again why they lost people to the enrollment because of qualifications for the trial and that some patients chose to leave the trial and AGN had to replace those numbers. IMO if those people that left the trial, perhaps they left the hospital because they could and were feeling better, or ran from the hospital, I would want to get as far away from death's door as possible, maybe the drug helped them, here's hoping. CEO also said that 150 enrollment would be reached by the time they came out with the data from the 75. - also AGN were now also looking at the use of Ifenprodil for cancers (liver and pancreatic). By the end of first week of December we'll know. p.s BioPub hosts were blown away with what AGN has accomplished so far being a smaller company. glta